Skip to main content
. 2020 Dec 21;70(12):2337–2348. doi: 10.1136/gutjnl-2020-323300

Table 4.

Correlation of intrahepatic and serological markers with the occurrence of HBV DNA integration

Patients’ characteristics At least one integration event (n=14) No integration events (n=26) P value*
Serological parameters
 Median serum ALT, U/L (IQR) 41 (27–90) 42 (28–67) 0.9
 Median serum HBV DNA, logIU/mL (IQR) 4.6 (3.6–5.6) 3.7 (3.1–5.0) 0.2
 Median serum HBsAg, logIU/mL (IQR) 3.9 (3.8–4.2) 3.2 (2.9–3.7) <0.001
 Median serum HBcrAg, logU/mL (IQR) 4.0 (3.9–4.5) 4.5 (3.4–5.4) 0.5
Intrahepatic parameters
 Median cccDNA (log copies/1000 cells) (IQR) 2.4 (1.9–2.7) 2.0 (1.0-2-6) 0.17
 Median itHBV DNA (log copies/1000 cells) (IQR) 3.6 (3.1–3.9) 3.5 (2.7–4.0) 0.6
 Median pgRNA (copies/1000 cells)† 3.1 (1.9–226) 4.5 (0.6–17) 0.73
Liver damage
 Ishak fibrosis stage
 0–2 10 (32.3) 21 (66.7) 0.6
 3–6 4 (44.4) 5 (55.5)

*P values were determined by Mann-Whitney U test for continuous variables and χ2 test for discrete variables.

†pgRNA levels were available for 21/40 patients analysed for HBV integration.

ALT, alanine aminotransferase; cccDNA, circular covalently closed DNA; HBcrAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; itHBV DNA, intrahepatic total HBV DNA; pgRNA, pregenomic RNA.